Home Transmembrane Transporters Proton Pump

Proton Pump

Choose Selective Proton Pump Inhibitors

Proton Pump Signaling Pathway Map

Proton Pump Signaling Pathways

Proton Pump Products

  • All (17)
  • Proton Pump Inhibitors (17)
  • New Proton Pump Products
Catalog No. Product Name Information Product Use Citations Product Validations
S1354 Lansoprazole Lansoprazole (A-65006, AG-1749) is a proton-pump inhibitor (PPI) that binds covalently to parietal cell H(+),K(+)-ATPase. Lansoprazole prevents the stomach from producing gastric acid.
Front Cell Dev Biol, 2021, 9:655559
J Virol, 2021, JVI.00190-21
Front Microbiol, 2019, 10:2790
S1389 Omeprazole Omeprazole is a proton pump inhibitor that blocks H(+)-K(+)-ATPase, used to treat dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, laryngopharyngeal reflux, and Zollinger–Ellison syndrome.
Theranostics, 2021, 11(5):2364-2380
J Virol, 2021, JVI.00190-21
Biosci Rep, 2021, BSR20200842
S1413 Bafilomycin A1 (Baf-A1) Bafilomycin A1(Baf-A1) is a vacuolar H+-ATPase inhibitor with IC50 of 0.44 nM. Bafilomycin A1 is found to inhibit autophagy while induces apoptosis.
Adv Sci (Weinh), 2021, e2100779
Mol Cell, 2021, S1097-2765(21)00729-2
ACS Nano, 2021, 10.1021/acsnano.1c06452
S1743 NEXIUM (esomeprazole magnesium) Esomeprazole Magnesium is a proton pump inhibitor to reduce gastric acid secretion through inhibition of H(+)/K(+)-ATPase in gastric parietal cells.
S2105 Pantoprazole Pantoprazole (SKF96022, BY-1023) is a proton pump inhibitor drug that inhibits gastric acid secretion. It works on gastric parietal cells to irreversibly inhibit (H+/K+)-ATPase function and suppress the production of gastric acid.
J Virol, 2021, JVI.00190-21
Front Microbiol, 2019, 10:2790
S2222 PF-3716556 PF 3716556 is a potent and selective P-CAB (potassium-competitive acid blocker), with pIC50 of 6.026 and 7.095 for the inhibition of porcine H+,K+-ATPase activity in ion-leaky and ion-tight assay, respectively, inhibits gastric acid secretion, displays no activity at Na+,K+-ATPase, used for the treatment of gastroesophageal reflux disease.
S3666 Ilaprazole Ilaprazole (IY-81149) is a new proton pump inhibitor (PPI) used in the treatment of dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD) and duodenal ulcer. It inhibits H+/K+-ATPase with an IC50 of 6.0 μM.
J Virol, 2021, JVI.00190-21
S4075 Zinc Pyrithione Zinc pyrithione (OM-1563) is an antifungal and antibacterial agent disrupting membrane transport by blocking the proton pump.
Cell Chem Biol, 2021, S2451-9456(21)00213-0
Biol Reprod, 2019, 100(2):468-478
Cell Syst, 2017, 4(6-:600-610
S4099 Dexlansoprazole Dexlansoprazole (T 168390, TAK 390), the dextrorotatory enantiomer of lansoprazole, is a proton pump inhibitor (PPI) formulated to have dual delayed-release properties. Dexlansoprazole selectively suppresses gastric acid secretion by direct inhibition of the H(+),K(+)-ATPase proton pump in the gastric parietal cell.
J Virol, 2021, JVI.00190-21
Front Microbiol, 2019, 10:2790
S4212 Tenatoprazole Tenatoprazole (TU-199) is a prodrug of the proton pump inhibitor (PPI) class, which inhibits proton transport with IC50 of 3.2 μM. Tenatoprazole labels only the gastric H(+),K(+)-ATPase alpha-subunit, approximately 2.6 nM/mg of tenatoprazole is bound to the H(+),K(+)-ATPase.
J Virol, 2021, JVI.00190-21
S4538 Pantoprazole sodium Pantoprazole (SKF96022, BY-1023) is a proton pump inhibitor drug that inhibits gastric acid secretion. It works on gastric parietal cells to irreversibly inhibit (H+/K+)-ATPase function and suppress the production of gastric acid.
J Virol, 2021, JVI.00190-21
S4665 Rabeprazole sodium Rabeprazole (Aciphex, Dexrabeprazole, Habeprazole) is an antiulcer drug in the class of proton pump inhibitors.
J Virol, 2021, JVI.00190-21
S4845 Rabeprazole Rabeprazole is an oral inhibitor of proton pump and blocks the production of acid by the stomach.
J Virol, 2021, JVI.00190-21
Biochem Pharmacol, 2021, 188:114525
BMC Pharmacol Toxicol, 2021, 22(1):44
S5058 Revaprazan Hydrochloride Revaprazan Hydrochloride (YH1885) is a new reversible proton pump inhibitor with long-lasting acid-suppressive effects. Revaprazan Hydrochloride reversibly inhibits H(+)/K(+)-ATPase via binding to the K+-binding site of the pump.
ACS Infect Dis, 2021, 10.1021/acsinfecdis.0c00754
S5502 Ilaprazole sodium Ilaprazole (IY-81149) sodium is the sodium salt form of ilaprazole, which is a proton pump inhibitor. Ilaprazole sodium irreversibly inhibits H(+)/K(+)-ATPase in a dose-dependent manner with IC50 of 6 μM in rabbit parietal cell preparation.
J Virol, 2021, JVI.00190-21
S5608New Pantoprazole sodium hydrate Pantoprazole (BY10232, SKF96022) sodium hydrate (Protonix) is a potent inhibitor of H+/K(+)-ATPase with IC50 of 6.8 μM.
J Virol, 2021, JVI.00190-21
S5658 Omeprazole Sodium Omeprazole Sodium is the sodium salt form of omeprazole, which is a proton pump inhibitor and suppresses gastric acid secretion. Omeprazole Sodium is a metabolism-dependent inhibitor (MDI) of CYP2C19.
Theranostics, 2021, 11(5):2364-2380
J Virol, 2021, JVI.00190-21
Biosci Rep, 2021, BSR20200842
S1354 Lansoprazole Lansoprazole (A-65006, AG-1749) is a proton-pump inhibitor (PPI) that binds covalently to parietal cell H(+),K(+)-ATPase. Lansoprazole prevents the stomach from producing gastric acid.
Front Cell Dev Biol, 2021, 9:655559
J Virol, 2021, JVI.00190-21
Front Microbiol, 2019, 10:2790
S1389 Omeprazole Omeprazole is a proton pump inhibitor that blocks H(+)-K(+)-ATPase, used to treat dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, laryngopharyngeal reflux, and Zollinger–Ellison syndrome.
Theranostics, 2021, 11(5):2364-2380
J Virol, 2021, JVI.00190-21
Biosci Rep, 2021, BSR20200842
S1413 Bafilomycin A1 (Baf-A1) Bafilomycin A1(Baf-A1) is a vacuolar H+-ATPase inhibitor with IC50 of 0.44 nM. Bafilomycin A1 is found to inhibit autophagy while induces apoptosis.
Adv Sci (Weinh), 2021, e2100779
Mol Cell, 2021, S1097-2765(21)00729-2
ACS Nano, 2021, 10.1021/acsnano.1c06452
S1743 NEXIUM (esomeprazole magnesium) Esomeprazole Magnesium is a proton pump inhibitor to reduce gastric acid secretion through inhibition of H(+)/K(+)-ATPase in gastric parietal cells.
S2105 Pantoprazole Pantoprazole (SKF96022, BY-1023) is a proton pump inhibitor drug that inhibits gastric acid secretion. It works on gastric parietal cells to irreversibly inhibit (H+/K+)-ATPase function and suppress the production of gastric acid.
J Virol, 2021, JVI.00190-21
Front Microbiol, 2019, 10:2790
S2222 PF-3716556 PF 3716556 is a potent and selective P-CAB (potassium-competitive acid blocker), with pIC50 of 6.026 and 7.095 for the inhibition of porcine H+,K+-ATPase activity in ion-leaky and ion-tight assay, respectively, inhibits gastric acid secretion, displays no activity at Na+,K+-ATPase, used for the treatment of gastroesophageal reflux disease.
S3666 Ilaprazole Ilaprazole (IY-81149) is a new proton pump inhibitor (PPI) used in the treatment of dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD) and duodenal ulcer. It inhibits H+/K+-ATPase with an IC50 of 6.0 μM.
J Virol, 2021, JVI.00190-21
S4075 Zinc Pyrithione Zinc pyrithione (OM-1563) is an antifungal and antibacterial agent disrupting membrane transport by blocking the proton pump.
Cell Chem Biol, 2021, S2451-9456(21)00213-0
Biol Reprod, 2019, 100(2):468-478
Cell Syst, 2017, 4(6-:600-610
S4099 Dexlansoprazole Dexlansoprazole (T 168390, TAK 390), the dextrorotatory enantiomer of lansoprazole, is a proton pump inhibitor (PPI) formulated to have dual delayed-release properties. Dexlansoprazole selectively suppresses gastric acid secretion by direct inhibition of the H(+),K(+)-ATPase proton pump in the gastric parietal cell.
J Virol, 2021, JVI.00190-21
Front Microbiol, 2019, 10:2790
S4212 Tenatoprazole Tenatoprazole (TU-199) is a prodrug of the proton pump inhibitor (PPI) class, which inhibits proton transport with IC50 of 3.2 μM. Tenatoprazole labels only the gastric H(+),K(+)-ATPase alpha-subunit, approximately 2.6 nM/mg of tenatoprazole is bound to the H(+),K(+)-ATPase.
J Virol, 2021, JVI.00190-21
S4538 Pantoprazole sodium Pantoprazole (SKF96022, BY-1023) is a proton pump inhibitor drug that inhibits gastric acid secretion. It works on gastric parietal cells to irreversibly inhibit (H+/K+)-ATPase function and suppress the production of gastric acid.
J Virol, 2021, JVI.00190-21
S4665 Rabeprazole sodium Rabeprazole (Aciphex, Dexrabeprazole, Habeprazole) is an antiulcer drug in the class of proton pump inhibitors.
J Virol, 2021, JVI.00190-21
S4845 Rabeprazole Rabeprazole is an oral inhibitor of proton pump and blocks the production of acid by the stomach.
J Virol, 2021, JVI.00190-21
Biochem Pharmacol, 2021, 188:114525
BMC Pharmacol Toxicol, 2021, 22(1):44
S5058 Revaprazan Hydrochloride Revaprazan Hydrochloride (YH1885) is a new reversible proton pump inhibitor with long-lasting acid-suppressive effects. Revaprazan Hydrochloride reversibly inhibits H(+)/K(+)-ATPase via binding to the K+-binding site of the pump.
ACS Infect Dis, 2021, 10.1021/acsinfecdis.0c00754
S5502 Ilaprazole sodium Ilaprazole (IY-81149) sodium is the sodium salt form of ilaprazole, which is a proton pump inhibitor. Ilaprazole sodium irreversibly inhibits H(+)/K(+)-ATPase in a dose-dependent manner with IC50 of 6 μM in rabbit parietal cell preparation.
J Virol, 2021, JVI.00190-21
S5608New Pantoprazole sodium hydrate Pantoprazole (BY10232, SKF96022) sodium hydrate (Protonix) is a potent inhibitor of H+/K(+)-ATPase with IC50 of 6.8 μM.
J Virol, 2021, JVI.00190-21
S5658 Omeprazole Sodium Omeprazole Sodium is the sodium salt form of omeprazole, which is a proton pump inhibitor and suppresses gastric acid secretion. Omeprazole Sodium is a metabolism-dependent inhibitor (MDI) of CYP2C19.
Theranostics, 2021, 11(5):2364-2380
J Virol, 2021, JVI.00190-21
Biosci Rep, 2021, BSR20200842
S5608New Pantoprazole sodium hydrate Pantoprazole (BY10232, SKF96022) sodium hydrate (Protonix) is a potent inhibitor of H+/K(+)-ATPase with IC50 of 6.8 μM.
J Virol, 2021, JVI.00190-21
Tags: proton pump inhibition | PPI therapy | PPI medication | PPIs drugs | proton pump inhibitors medications | proton pump inhibitor drugs | PPI treatment | proton pump inhibitors list | proton pump inhibitor therapy | proton pump inhibitor treatment | proton pump inhibitors cancer | PPI prescription | proton pump inhibitor guidelines | proton pump inhibitor function | proton pump inhibitors contraindications | PPI contraindications proton pump inhibitor review